Jump to content

All Activity

This stream auto-updates     

  1. Today
  2. Related Articles [Gastrointestinal comorbidity and symptoms associated with depression in patients aged over 60 years]. Semergen. 2019 May 16;: Authors: Aguado A, García Del Álamo M Abstract OBJECTIVE: A study was carried out on the prevalence of gastrointestinal diagnoses and symptoms associated with depression. MATERIAL AND METHODS: A cross-sectional observational study was conducted in Primary Care in 2017. All patients aged 60 years or more with depression were included from the health care centre (N=2312), and were compared to the total patients that visited the centre from the same age group without depression (N=11049). The variables collected were age, gender and the codes for gastrointestinal symptoms and chronic conditions. These were obtained from the computerised medical files. The prevalence was calculated for both groups, and included the odds ratio (OR) and 95% confidence interval (CI). RESULTS: More than one-third (38.0%) of patients with depression have chronic gastrointestinal diseases, 64.7% have gastrointestinal symptoms, and 74.7% have either of them. The conditions with strongest associations are: irritable bowel syndrome OR: 2.00 (95% CI: 1.51-2.64), congenital anomaly 1.83 (1.17-2.86), other peptic ulcers 1.75 (1.28-2.40), diverticular disease 1.73 (1.52-1.97), cholecystitis/cholelithiasis 1.59 (1.36-1.86), liver disease 1.55 (1.32-1.82), viral hepatitis 1.50 (1.12-2.02), and oesophageal diseases 1.45 (1.24-1.69). Symptoms with a statistically significant OR were: anorexia 2.81 (1.75-4.50), nausea/vomiting 2.19 (1.79-2.67), constipation 1.96 (1.77-2.18), flatulence 1.78 (1.48-2.14), dysphagia 1,72 (1.30-2.28), abdominal pain 1.69 (1.57-1.82), dyspepsia 1.56 (1.30-1.87), and heartburn 1.55 (1.26-1.92). CONCLUSIONS: Gastrointestinal comorbidity is very common in patients over 60 years-old with depression. Three-quarters of the patients have chronic gastrointestinal diseases or symptoms. The conditions with strongest associations are irritable bowel syndrome, congenital anomalies, other peptic ulcers, and diverticular disease. The symptoms with strongest associations are anorexia, nausea/vomiting, constipation, flatulence, dysphagia, abdominal pain, dyspepsia, and heartburn. PMID: 31105031 [PubMed - as supplied by publisher] View the full article
  3. Impact of occupational stress on irritable bowel syndrome pathophysiology and potential management in active duty noncombat Greek military personnel: a multicenter prospective survey. Eur J Gastroenterol Hepatol. 2019 May 16;: Authors: Papaefthymiou A, Doulberis M, Kountouras J, Kolokytha C, Galanopoulos M, Liatsos C, Kyriakos N, Giakoumis M, Papadomichelakis M, Polyzos SA, Kotronis G, Katsinelos P Abstract INTRODUCTION: Irritable bowel syndrome (IBS) is one of the gut-brain axis interaction disorders. It has global distribution with varying prevalence and particular financial and psychological consequences. IBS has been associated with stress and anxiety, conditions that are usually prevalent in the army. There are scarce data investigating the impact of IBS on noncombat active duty military without reports of Greek military or stress in the occupational environment. MATERIALS AND METHODS: The main exclusion criteria in our noncombat military multicenter prospective survey were gastrointestinal pathologies, malignancies, hematochezia, recent infections and antibiotics prescription, and pregnancy. Questionnaires included a synthesis of baseline information, lifestyle, and diet, psychological and stress-investigating scales and the IBS diagnosis checklist. Hospital Anxiety and Depression Scale and Rome IV criteria were utilized. RESULTS: Among 1605 participants included finally, the prevalence of IBS was 8% and 131 cases were identified. Women were more vulnerable to IBS, although male sex was prevalent at a ratio of 3.5 : 1 (male:female) in the entire sample. The mean age of all participants was 23.85 years; most of the IBS patients were older than thirty. Abnormal anxiety scores and high levels of occupational stress were related to an IBS diagnosis. DISCUSSION: This prospective multicenter survey showed, for the first time, the potential impact of occupational stress on IBS in active duty noncombat Greek Military personnel. The diagnosis of IBS by questionnaire is a quick, affordable way that can upgrade, by its management, the quality of life and relieve from the military burden. Our results are comparable with previous studies, although large-scale epidemiological studies are required for the confirmation of a possible causative relationship. PMID: 31107738 [PubMed - as supplied by publisher] View the full article
  4. Yesterday
  5. The Impact of a 4-Week Low-FODMAP and mNICE Diet on Nutrient Intake in a Sample of US Adults with Irritable Bowel Syndrome with Diarrhea. J Acad Nutr Diet. 2019 May 15;: Authors: Eswaran S, Dolan RD, Ball SC, Jackson K, Chey W Abstract BACKGROUND: A diet low in fermentable oligosaccharides, disaccharides, monosaccharides, and polyols (FODMAP) has gained increasing acceptance for the treatment of irritable bowel syndrome but safety concerns have been raised regarding nutritional adequacy. Changes in nutrient intake during the elimination phase of the low-FODMAP diet remain predominantly unknown. OBJECTIVE: To determine changes in the mean reported daily nutrient content before and after 4 weeks of a low-FODMAP diet vs modified National Institute for Health and Clinical Excellence (mNICE) dietary intervention and to identify nutritional inadequacies based on comparison to the Dietary Reference Intakes in patients with irritable bowel syndrome-diarrhea subtype. DESIGN: Post hoc analysis of a randomized controlled trial entailing a 4-week trial period comparing the low-FODMAP and mNICE diets. PARTICIPANTS AND SETTING: A total of 78 patients (41 low FODMAP and 37 mNICE) meeting the Rome III criteria for irritable bowel syndrome-diarrhea subtype were consecutively recruited from gastroenterology and primary care clinics at the University of Michigan Medical Center between October 2012 and November 2015. METHODS: Participants randomized to the low-FODMAP arm were instructed to decrease their dietary intake of FODMAPs, whereas participants randomized to the mNICE intervention arm were instructed to eat small frequent meals, avoid trigger foods, and avoid excess alcohol and caffeine. MAIN OUTCOME MEASURES: Post hoc evaluation for presence of micronutrient deficiencies per Dietary Reference Intakes when implementing low-FODMAP vs mNICE dietary interventions. Dietary intake was analyzed via 3-day food diaries at baseline and during the final week of the assigned diet. STATISTICAL ANALYSES PERFORMED: A post hoc analysis utilizing either a t test or χ2 analysis was conducted between before and after data. RESULTS: Both diets resulted in fewer daily kilocalories consumed, fewer number of daily meals consumed, and less daily carbohydrate intake. Among the patients following the low-FODMAP diet, there was a statistically significant decrease from baseline in several micronutrients, which was not observed in the mNICE cohort. However, these differences in the low-FODMAP group remained significant only for riboflavin after correcting for calorie-adjusted nutrient intake. Comparing Dietary Reference Intakes of participants pre- and postintervention, fewer patients met the Dietary Reference Intakes for thiamin and iron in the low FODMAP group, and for calcium and copper in the mNICE group. CONCLUSIONS: During a 4-week dietary intervention, the mean daily intake of most micronutrients remained stable and within the Recommended Dietary Allowances for both diets. Although decrease in several micronutrients was observed with implementation of the low-FODMAP diet relative to the mNICE diet, most of these disappeared after adjusting for energy intake. PMID: 31103370 [PubMed - as supplied by publisher] View the full article
  6. Last week
  7. Related Articles Rifamycin SV exhibits strong anti-inflammatory in vitro activity through pregnane X receptor stimulation and NFκB inhibition. Drug Metab Pharmacokinet. 2019 Jan 17;: Authors: Rosette C, Agan FJ, Rosette N, Moro L, Mazzetti A, Hassan C, Gerloni M Abstract Rifamycin SV (rifamycin), is a member of the ansamycin family of antimicrobial compounds which kills bacteria commonly associated with infectious diarrhea and other enteric infections. Rifamycin has been found to be effective in experimental animal models of gut inflammation and its efficacy in these settings has been attributed partially to immunomodulatory non-bactericidal activities. This study aimed to further evaluate the anti-inflammatory activities of rifamycin by analyzing its effect on two key regulators of inflammation: PXR and NFκB. Rifamycin stimulated PXR transcriptional activity in two PXR reporter cell lines and induced expression of two genes known to be regulated by PXR and are directly involved in cellular detoxification: CYP3A4 and PgP. Moreover, CYP3A4 metabolic activity was induced by rifamycin in HepG2 cells. Rifamycin also antagonized TNFα and LPS-induced NFκB activities and inhibited IL1β-induced synthesis of inflammatory chemokine, IL8. Although reciprocal regulation of PXR and NFkB by rifamycin was not directly addressed, the data suggest that in the absence of PXR, inhibition of NFκB by rifamycin is not dependent on PXR stimulation. Thus, rifamycin exhibits potent anti-inflammatory activities, characterized by in vitro PXR activation and concomitant CYP3A4 and PgP induction, in parallel with potent NFκB inhibition and concomitant IL8 inhibition. PMID: 31101589 [PubMed - as supplied by publisher] View the full article
  8. Many Patients With Irritable Bowel Syndrome Have Atypical Food Allergies Not Associated With Immunoglobulin E. Gastroenterology. 2019 May 14;: Authors: Fritscher-Ravens A, Pflaum T, Mösinger M, Ruchai Z, Röcken C, Milla PJ, Das M, Böttner M, Wedel T, Schuppan D Abstract BACKGROUND & AIMS: Confocal laser endomicroscopy (CLE) is a technique that permits real-time detection and quantification of changes in intestinal tissues and cells, including increases in intraepithelial lymphocytes and fluid extravasation through epithelial leaks. Using CLE analysis of patients with irritable bowel syndrome (IBS), we found that more than half have responses to specific food components. Exclusion of the defined food led to long-term symptom relief. We used results of CLE to detect reactions to food in a larger patient population, and analyzed duodenal biopsies and fluid from patients to investigate mechanisms of these reactions. METHODS: In a prospective study, 155 patients with IBS received 4 challenges with each of 4 common food components via the endoscope, followed by CLE, at a tertiary medical center. Classical food allergies were excluded by negative results from immunoglobulin E serology analysis and skin tests for common food antigens. Duodenal biopsies and fluid were collected 2 weeks before and immediately following CLE, and analyzed by histology, immunohistochemistry, reverse transcription PCR, and immunoblots. Results from patients who had a response to food during CLE (CLE+) were compared with results from patients who did not have a reaction during CLE (CLE-) or healthy individuals (controls). RESULTS: Of the 108 patients who completed the study, 76 were CLE+ (70%), and 46 of these (61%) reacted to wheat. CLE+ patients had a 4-fold increase in prevalence of atopic disorders compared with controls (P=.001). Numbers of intraepithelial lymphocytes were significantly higher in duodenal biopsies from CLE+ vs CLE- patients or controls (P=.001). Expression of claudin-2 increased from crypt to villus tip (P<.001) and was upregulated in CLE+ patients, compared to CLE- patients or controls (P=.023). Levels of occludin were lower in duodenal biopsies from CLE+ patients vs controls (P=.022), and lowest in villus tips (P<.001). Levels of mRNAs encoding inflammatory cytokines were unchanged in duodenal tissues after CLE challenge, but eosinophil degranulation increased, and levels of eosinophilic cationic protein were higher in duodenal fluid from CLE+ patients than controls (P=.03). CONCLUSIONS: In a CLE analysis of patients with IBS, we found that more than 50% of patients could have nonclassical food allergy, with immediate disruption of the intestinal barrier upon exposure to food antigens. Duodenal tissues from patients with responses to food components during CLE had immediate increases in expression of claudin-2 and decreases in occludin. CLE+ patients also had increased eosinophil degranulation, indicating an atypical food allergy characterized by eosinophil activation. PMID: 31100380 [PubMed - as supplied by publisher] View the full article
  9. Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain. Clin Gastroenterol Hepatol. 2019 May 14;: Authors: McOmber M, Rafati D, Cain K, Devaraj S, Weidler EM, Heitkemper M, Shulman RJ Abstract BACKGROUND & AIMS: Increased gut permeability might contribute to the pathogenesis of irritable bowel syndrome or functional abdominal pain (IBS or FAP). We investigated whether siblings and parents of children with IBS or FAP have increased gut permeability. METHODS: We performed permeability tests (using sucrose, lactulose, mannitol, and sucralose) on 29 siblings and 43 parents of children with IBS or FAP, and 43 children (controls) and 42 parents of controls, from primary and secondary care. Permeability studies were repeated in 7 siblings and 37 parents of children with IBS or FAP and 23 controls and 36 parents of controls following ingestion of 400 mg of ibuprofen. Percent recovery of sucrose was calculated based on analyses of urine, collected overnight; the lactulose/mannitol ratio and percent recovery of sucralose were based on analyses of urine samples collected over a 24-hour period. RESULTS: When we controlled for age, sex, and family membership, siblings of children with IBS or FAP had increased small bowel permeability (urinary lactulose/mannitol ratio) vs controls (P=.004). There was no difference in gastroduodenal (percent sucrose recovery) or colonic (percent sucralose recovery) permeability between groups. Similarly, parents of children with IBS or FAP also had increased small bowel permeability, compared with parents of controls (P=.015), with no differences in gastric or colonic permeability. After administration of ibuprofen, gastroduodenal and small bowel permeability tended to be greater in IBS or FAP siblings (P=.08) and gastroduodenal permeability tended to be greater in IBS or FAP parents (P=0.086). CONCLUSIONS: Siblings and parents of children with IBS or FAP have increased baseline small intestinal permeability compared with control children and their parents. These results indicate that there are familial influences on gastrointestinal permeability in patients with IBS or FAP. PMID: 31100459 [PubMed - as supplied by publisher] View the full article
  10. cuba

    Monash app

    Is the Fodmap app by Monash worth the money? I have tried free types before but are very basic. Cheers Sent from my SM-G960F using Tapatalk
  11. Related Articles Corrigendum to "A Randomized, Double-Blind, Placebo-Controlled Trial: The Efficacy of Multispecies Probiotic Supplementation in Alleviating Symptoms of Irritable Bowel Syndrome Associated with Constipation". Biomed Res Int. 2019;2019:9042956 Authors: Mezzasalma V, Manfrini E, Ferri E, Sandionigi A, Ferla B, Schiano I, Michelotti A, Nobile V, Labra M, Di Gennaro P Abstract [This corrects the article DOI: 10.1155/2016/4740907.]. PMID: 31093503 [PubMed] View the full article
  12. Related Articles Cannabinoid-induced relief of hypermotility in a rat model of the irritable bowel syndrome. Neurogastroenterol Motil. 2019 Jun;31(6):e13613 Authors: Galligan JJ Abstract Cannabinoid-2 receptor agonists may be useful in treating intestinal motility disorders. PMID: 31094052 [PubMed - in process] View the full article
  13. Rebamipide increases the disaccharidases activity in patients with enteropathy with impaired membrane digestion. Pilot study. Ter Arkh. 2019 Mar 18;91(2):25-31 Authors: Parfenov АI, Belostotsky NI, Khomeriki SG, Akhmadullina OV, Bykova SV, Sabelnikova EA, Dbar SR Abstract AIM: To evaluate the effectiveness of enteroprotector Rebamipide in the treatment of enteropathy with impaired membrane digestion (EIMD). MATERIALS AND METHODS: We examined 102 patients aged 18 to 50 years (41 men and 61 women) with clinical signs of irritable bowel syndrome (n=65), functional diarrhea (n=33), and functional constipation (n=4) according to Rome IV criteria (2016). The activities of glucoamylase (GA), maltase, sucrase and lactase were determined by Dahlquist-Trinder method in duodenal biopsies obtained during esophagogastroduodenoscopy. The control group consisted of 20 healthy people aged 23-47. They showed following average enzyme activity: lactase - 42±13 ng glucose on 1 mg of tissue per minute, GA - 509±176, maltase - 1735±446, sucrase - 136±35 ng glucose on 1 mg of tissue per minute. These numbers were taken as the norm. RESULTS: The activity of the disaccharidases was reduced in 89.2% out of 102 patients, and they were diagnosed with EIMD. Thirteen patients with EIMD were recommended to maintain the FODMAP diet and take enteroprotector Rebamipide 100 mg 3 times a day for 12 weeks. After 3 months 11 patients reported decreased or no flatulence, abdominal pain, stool disorder; 2 patients reported no change. The activity of GA increased to an average of 149±82 (by 78%, p=0.016), maltase - to 864±472 (by 131%, p=0.0019), sucrase - 63±35 (by 95%, p=0.0041) and lactase - 10±8 ng glucose on 1 mg of tissue per minute. The activity of lactase did not change. CONCLUSION: We discovered a previously unknown phenomenon of the disaccharidases activity increase in duodenal mucosa and improved carbohydrates tolerance in the patients with EIMD taking Rebamipide in the dose 300 mg/day for 12 weeks. PMID: 31094168 [PubMed - in process] View the full article
  14. 8 Morning Habits That Can Prevent IBS BustleWhen you begin a new day, you want to feel healthy and energized so that you can accomplish everything on your to-do list. You might swear by a morning cup ... View the full article
  15. In IBS, Pathophysiologic Factors Can Worsen Symptoms, Quality of Life Consultant360Visceral hypersensitivity, abnormal colonic transit, and psychologic factors are all associated with irritable bowel syndrome (IBS), according to a recent study. View the full article
  16. Common diarrhea pathogen unknown to many people EurekAlertSalmonella, genetically modified foods and microplastics in food head the awareness scale of health and consumer topics in Germany. Despite this, more than ... View the full article
  17. Don't miss Rome Board Members @DDW! May 19th, Room 25ABC, 8 - 9:30 am for How to Manage Difficult GI Consultations #DDW19 (Feed generated with FetchRSS) View the full article
  18. Clinical Value of Fecal Calprotectin. Crit Rev Clin Lab Sci. 2019 May 15;:1-37 Authors: Ricciuto A, Griffiths AM Abstract Inflammatory bowel disease (IBD) denotes a group of chronic incurable disorders characterized by relapsing-remitting inflammation of the gastrointestinal tract. IBD represents a growing global burden with a prevalence exceeding 0.3% in the Western world and an accelerating incidence in newly industrialized countries. The target for treating IBD has shifted in recent years from symptom control to mucosal healing (MH), which has been shown to be associated with favourable long-term outcomes. The gold standard for ascertaining MH is endoscopic assessment, but endoscopy is limited by its invasive nature, high cost and finite availability. Surrogate biomarkers are therefore of great utility. Calprotectin, a cytosolic protein derived predominantly from neutrophils, is now widely used in this capacity. Calprotectin is found in various bodily fluids at concentrations proportional to the degree of inflammation, including in feces at levels roughly six times higher than in the blood. Fecal calprotectin (FCP) therefore reflects intestinal inflammation. Various assays, including point-of-care and home-based tests, are now available for measuring FCP. FCP is used for screening purposes, to aid in distinguishing inflammatory from non-inflammatory gastrointestinal conditions like irritable bowel syndrome (IBS), as well as in the monitoring of known IBD. The aims of this review are to provide an overview of the methods used to measure FCP and to review the evidence supporting the use of FCP in IBD, particularly as it pertains to screening, monitoring and predicting disease relapse. PMID: 31088326 [PubMed - as supplied by publisher] View the full article
  19. The disease burden associated with Campylobacter spp. in Germany, 2014. PLoS One. 2019;14(5):e0216867 Authors: Lackner J, Weiss M, Müller-Graf C, Greiner M Abstract Bacteria of the genus Campylobacter are an important cause of human illness worldwide. Campylobacter infections are expressed as gastroenteritis and can lead to severe sequelae like reactive arthritis, Guillain-Barré syndrome, irritable bowel syndrome and inflammatory bowel disease. In Germany, Campylobacter-associated gastroenteritis cases are notifiable but there is no reporting obligation for the sequelaes and the disease burden is clearly underestimated. The aim of our study was to quantify reliably the current disease burden of all Campylobacter spp.-associated diseases for Germany with the method of disability-adjusted life years (DALYs). DALYs combine mortality and morbidity in a single summary measure, whereby one DALY represents the loss of one year in full health. For acute gastroenteritis, we estimated 967 DALYs of which only 484 DALYs were detected within the reporting system. Overall, we estimated that 8811 DALYs were caused by the campylobacter-related diseases known so far. 98% of the DALYs were associated with morbidity and 2% with mortality. Mortality was caused by the health outcomes Gastroenteritis and Guillain-Barré syndrome exclusively. PMID: 31091282 [PubMed - in process] View the full article
  20. Parasympathetic activity correlates with subjective and brain responses to rectal distension in healthy subjects but not in non-constipated patients with irritable bowel syndrome. Sci Rep. 2019 May 14;9(1):7358 Authors: Kano M, Yoshizawa M, Kono K, Muratsubaki T, Morishita J, Van Oudenhove L, Yagihashi M, Mugikura S, Dupont P, Takase K, Kanazawa M, Fukudo S Abstract The nociceptive and autonomic nervous systems (ANS) are significantly intertwined. Decoupling of these systems may occur in pathological pain conditions, including irritable bowel syndrome (IBS). We investigated ANS activity and its association with visceral perception and brain activity during rectal distention in 27 patients with non-constipated IBS and 33 controls by assessing heart rate variability (HRV) using electrocardiography at rest, before, and during colorectal distention. Brain responses to colorectal distention were measured using functional magnetic resonance imaging and correlated with individual ANS function parameters. The IBS group displayed blunted sympathovagal balance [low/high-frequency ratio (LF:HF) of HRV] in response to colorectal distention compared with controls (P = 0.003). In controls, basal parasympathetic tone (HF component of HRV) was significantly negatively correlated with toleration threshold to the rectal distention, but not in patients with IBS (group comparison P = 0.04). Further, a positive correlation between baseline HF values and neural responses to rectal distension was found in the right caudate, bilateral dorsolateral anterior cingulate cortex, and pregenual anterior cingulate cortex in the control group but not in the IBS group. The results indicate abnormal interactions between ANS activity and the brain mechanisms underlying visceral perception in patients with IBS. PMID: 31089154 [PubMed - in process] View the full article
  21. Related Articles Optical recording reveals topological distribution of functionally classified colorectal afferent neurons in intact lumbosacral DRG. Physiol Rep. 2019 May;7(9):e14097 Authors: Guo T, Bian Z, Trocki K, Chen L, Zheng G, Feng B Abstract Neuromodulation as a non-drug alternative for managing visceral pain in irritable bowel syndrome (IBS) may target sensitized afferents of distal colon and rectum (colorectum), especially their somata in the dorsal root ganglion (DRG). Developing selective DRG stimulation to manage visceral pain requires knowledge of the topological distribution of colorectal afferent somata which are sparsely distributed in the DRG. Here, we implemented GCaMP6f to conduct high-throughput optical recordings of colorectal afferent activities in lumbosacral DRG, that is, optical electrophysiology. Using a mouse ex vivo preparation with distal colorectum and L5-S1 DRG in continuity, we recorded 791 colorectal afferents' responses to graded colorectal distension (15, 30, 40, and 60 mmHg) and/or luminal shear flow (20-30 mL/min), then functionally classified them into four mechanosensitive classes, and determined the topological distribution of their somata in the DRG. Of the 791 colorectal afferents, 90.8% were in the L6 DRG, 8.3% in the S1 DRG, and only 0.9% in the L5 DRG. L6 afferents had all four classes: 29% mucosal, 18.4% muscular-mucosal, 34% low-threshold (LT) muscular, and 18.2% high-threshold (HT) muscular afferents. S1 afferents only had three classes: 19.7% mucosal, 34.8% LT muscular, and 45.5% HT muscular afferents. All seven L5 afferents were HT muscular. In L6 DRG, somata of HT muscular afferents were clustered in the caudal region whereas somata of the other classes did not cluster in specific regions. Outcomes of this study can directly inform the design and improvement of next-generation neuromodulation devices that target the DRG to alleviate visceral pain in IBS patients. PMID: 31087524 [PubMed - in process] View the full article
  22. Related Articles Zelnorm, an agonist of 5-Hydroxytryptamine 4-receptor, acts as a potential antitumor drug by targeting JAK/STAT3 signaling. Invest New Drugs. 2019 May 14;: Authors: Zhang L, Song Q, Zhang X, Li L, Xu X, Xu X, Li X, Wang Z, Lin Y, Li X, Li M, Su F, Wang X, Qiu P, Guan H, Tang Y, Xu W, Yang J, Zhao C Abstract The Janus kinase (JAK)/signal transducer and activator of transcription 3 (STAT3) signaling pathway plays central roles in cancer cell growth and survival. Drug repurposing strategies have provided a valuable approach for developing antitumor drugs. Zelnorm (tegaserod maleate) was originally designed as an agonist of 5-hydroxytryptamine 4 receptor (5-HT4R) and approved by the FDA for treating irritable bowel syndrome with constipation (IBS-C). Through the use of a high-throughput drug screening system, Zelnorm was identified as a JAK/STAT3 signaling inhibitor. Moreover, the inhibition of STAT3 phosphorylation by Zelnorm was independent of its original target 5-HT4R. Zelnorm could cause G1 cell cycle arrest, induce cell apoptosis and inhibit the growth of a variety of cancer cells. The present study identifies Zelnorm as a novel JAK/STAT3 signaling inhibitor and reveals a new clinical application of Zelnorm upon market reintroduction. PMID: 31087223 [PubMed - as supplied by publisher] View the full article
  23. Everyone meet Priya! Our first dietitian from India to complete the Monash #FODMAP Online Course. We're so happy to have Priya here, teaching us about the challenges of implementing a #LowFODMAP Diet in India. Find her details in our Dietitian Directory https://bit.ly/2ZkhHhK (Feed generated with FetchRSS) View the full article
  24. That's really good to hear. Working with a Dietitian is recommended for that very reason.
  25. Jeffrey, I just read your article and you answered a lot of questions I had! I have so restricted what I was eating (proving dietitians' worries are spot on), was feeling better, but was miserable thinking I had to maintain this paltry way of eating. Now I find that I can slowly re-introduce other foods. Woohoo! If truth be told, each time a have a flare-up, I know exactly why - I have eaten everything not tied down, sort of a celebration that I was feeling so great. I intend to follow the suggestions in your article, and I thank you from the bottom of my heart!
  26. Our team was recently interviewed by consumer advocacy group @choiceaustralia about the low FODMAP diet and whether it really works for people with IBS. Read the interview summary on our blog here: http://ow.ly/u7mc50uaGGm (Feed generated with FetchRSS) View the full article
  27. Combination therapy advisable for IBS Medical XpressThe more abnormalities in intestinal and brain function that IBS sufferers have, the more severe their symptoms of this functional bowel disorder, and the more ... View the full article
  28. For those that listened to Episode #1 of the IBS Chat Podcast, I'll be recording at least 6 new episodes at DDW in San Diego later this week and next. You can follow the podcasts as they are posted here or on our website https://www.ibspatient.org/podcasts or subscribe on iTunes or Google Play. This is the line up of guests/topics. Kate Scarlata, RDN - A Boston-based registered and licensed dietitian as well as a New York Times Best Selling Author with 25+ years of experience. Kate specializes in the Low FODMAP Diet, IBS and SIBO along with other digestive health conditions. Dr. William Chey - Gastroenterologist, FACG, Director in the Division of Gastroenterology, Michigan Medicine Gastroenterology Clinic, Ann Arbor, Leading investigator of food and functional GI diseases Dr. Mark Pimentel - Gastroenterologist, Program Director, Medically Associated Science and Technology (MAST) Program Cedar-Sinai Medical Center, Leading investigator gut microbiome and SIBO. Dr. Jeffrey Lackner - PhD, Psychologist, Director of the Behavioral Medicine Clinic and an associate professor in the Department of Medicine at the University at Buffalo School of Medicine. Primary research interests include biobehavioral aspects of irritable bowel syndrome including the use of cognitive behavioral therapy and self management of IBS. Matt Mitcho - CEO of Gemelli Biotech, maker of IBS-Smart a second generation non-invasive blood test for diagnosing IBS which looks at levels of anti-vinculin and anti-CDTB. Poster abstract presenters - a recap of the leading research papers at DDW
  1. Load more activity

  • Create New...